ArticleNature metabolism2024
Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes.
Abstract read
In one paragraph
Article in Nature metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Adipose Tissue Remodeling Beyond Weight Loss: New Insights Into Incretin-Based Therapies and Bariatric Surgery.Current obesity reports · 2026Review
- Glycemic and bodyweight effects ofScience advances · 2026Article
- Clinical Potential of GIP in Type 2 Diabetes and Obesity.Diabetes care · 2026Review
- Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?Journal of the Endocrine Society · 2026Review
- The evolving landscape of obesity pharmacotherapy.Nature reviews. Drug discovery · 2026Review
- Recent developments in GPCR signalling in appetite regulation.Bioscience reports · 2026Review
- Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk.European heart journal · 2026Article
- Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations.Molecular metabolism · 2026Article
- The evolving landscape of pharmacogenomics: Current achievements and future directions.Pharmacological reviews · 2026Review
- The expanding landscape of GLP-1 medicines.Nature medicine · 2026Review
- Incretin hormones and obesity.The Journal of physiology · 2025Review
- Deliberating the striking effect of dual GLP-1R and GIPR agonists on "Diabesity" in light of precision medicine and pharmacogenomics.Metabolism open · 2025Review
- Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs.Current obesity reports · 2025Review
- Review
- A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity.Diabetes · 2025Review
- GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale.Diabetes · 2025Review
- Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling: Making the Case for a Functionally GInternational journal of molecular sciences · 2025Review
- Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy.Cell reports. Medicine · 2025Article
- GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice.Nature metabolism · 2025Article
- Rare MTNR1B variants causing diminished MT2 signalling associate with elevated HbADiabetologia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Hüsün S Kizilkaya *Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-2406-9507
Kimmie V Sørensen *Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-3861-4484
Jakob S Madsen *Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-2841-7284
Peter LindquistDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-8120-3074
Jonathan D DourosNovo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.
Jette Bork-JensenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Alessandro BerghellaDepartment of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Peter A GerlachDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0009-0000-7108-0026
Lærke S GasbjergDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-7880-8515
Jacek MokrosińskiNovo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0001-5008-0457
Stephanie A MoweryNovo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.
Patrick J KnerrNovo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.
Brian FinanNovo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-6467-0447
Jonathan E CampbellDuke Molecular Physiology Institute, Duke University Durham, Durham, NC, USA.ORCID http://orcid.org/0000-0003-4358-6331
David A D'AlessioDuke Molecular Physiology Institute, Duke University Durham, Durham, NC, USA.ORCID http://orcid.org/0000-0003-4155-4870
Diego Perez-TilveDepartment of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID http://orcid.org/0000-0002-0351-4133
Felix FaasDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Signe MathiasenDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jørgen RungbyDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Henrik T SørensenDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-4299-7040
Allan VaagSteno Diabetes Center Copenhagen, Herlev, Denmark.
Jens S NielsenSteno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.ORCID http://orcid.org/0000-0003-3179-1186
Jens-Christian HolmNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jeannet LauenborgDepartment of Obstetrics and Gynecology, Copenhagen University Hospital Herlev, Herlev, Denmark.ORCID http://orcid.org/0000-0002-8485-3793
Peter DammDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-2067-5246
Oluf PedersenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-3321-3972
Allan LinnebergDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-0994-0184
Bolette HartmannDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-8509-2036
Jens J HolstDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-6853-3805
Torben HansenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-8748-3831
Shane C WrightDepartment of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-7470-5068
Volker M LauschkeDepartment of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-1140-6204
Niels GrarupNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. niels.grarup@sund.ku.dk.ORCID http://orcid.org/0000-0001-5526-1070
Alexander S HauserDepartment of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark. alexander.hauser@sund.ku.dk.ORCID http://orcid.org/0000-0003-1098-6419
Mette M RosenkildeDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. rosenkilde@sund.ku.dk.ORCID http://orcid.org/0000-0001-9600-3254
Funding
Lundbeckfonden (Lundbeck Foundation) R278-2018-180Novo Nordisk Fonden (Novo Nordisk Foundation) NNF17SA0031406Novo Nordisk Foundation Center for Basic Metabolic Research (NovoNordisk Foundation Center for Basic Metabolic Research) NNF18CC0034900Svenska Läkaresällskapet (Swedish Society of Medicine) PD20-0153
Abstract
Incretin-based therapies are highly successful in combatting obesity and type 2 diabetes
Indexed as
beta-ArrestinsPhenotypeReceptors, Gastrointestinal HormoneAnimalsbeta-Arrestin 2Diabetes Mellitus, Type 2Gastric Inhibitory PolypeptideGenetic VariationGlucagon-Like Peptide-1 ReceptorHumansMaleMiceObesitySignal Transductionbeta-Arrestin 2beta-ArrestinsGastric Inhibitory Polypeptidegastric inhibitory polypeptide receptorGlucagon-Like Peptide-1 ReceptorReceptors, Gastrointestinal Hormone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.